Login to Your Account



ImmuPharma, Cephalon Ink Potential $500M Lupuzor Deal

By Nuala Moran


Wednesday, November 26, 2008
LONDON - ImmuPharma plc took $15 million up front as the first payment in a potential $500 million deal, as it signed an agreement giving Cephalon Inc. the option on an exclusive, worldwide license to Lupuzor in the treatment of systemic lupus erythematosus. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription